Bayer and Orion’s Nubeqa secures FDA approval in non-metastatic castration-resistant prostate cancer
July 31, 2019Research and Development, Sales and Marketing Bayer, Cancer, Nubeqa, orion, pharma, prostate cancer
The FDA has awarded approval under its Priority Review pathway to Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate …
Cigarette smoke causes superbug to become more drug resistant, study shows
July 30, 2019Research and Development AMR, MRSA, cigarettes smoke, drug resistance, pharma, smoking
Cigarette smoke can make certain strains of the bacteria Methicillin-resistant Staphylococcus aureus (MRSA) more resistant to antibiotics, according to a …
Bayer’s Vitravki poised to become first tumour-agnostic therapy in EU following CHMP recommendation
July 30, 2019Manufacturing and Production, Sales and Marketing Bayer, CHMP, Cancer, EU, Vitrakvi, pharma
Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) could be set to become the European Union’s first drug approved in a tumour-agnostic …
Extremely antibiotic resistant superbugs spreading in hospitals across Europe
July 30, 2019Manufacturing and Production AMR, Antibiotics, drug resistance, drug resistant bacteria, pharma
Antibiotic resistant superbugs are spreading in hospitals in Europe, according to a study published in Nature Microbiology. The research shows …
MSD’s Keytruda combo hits primary endpoint at Phase 3 in triple-negative breast cancer
July 30, 2019Manufacturing and Production, Research and Development Cancer, MSD, breast cancer, keytruda, pharma
MSD’s blockbuster anti-PD-L1 immunotherapy Keytruda (pembrolizumab) has impressed in newly released Phase 3 data; the company announced that, when combined …
Teva, Endo and Teikoku pay $70 million settlement to California
July 30, 2019Manufacturing and Production
Three pharmaceutical companies have agreed to pay $70 million to the state of California for keeping drug prices artificially high. …
Pfizer to combine off-patent drug unit Upjohn with Mylan
July 30, 2019Manufacturing and Production M&A, MA, Mylan, Pfizer, Upjohn, biosimilars, generics, mergers
Pfizer’s off-patent drug unit Upjohn is combining with Mylan to create a new global pharmaceutical company focused on the low-price …
The patient is always right: Extracting the full value of PROMs
July 29, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, PROs, UK, feature, patient reported outcomes, patient-reported outcomes, pharma
Patient-reported outcomes measures are an invaluable tool in ensuring that the patient remains in the driving seat when it comes …
Roche’s Tecentriq combo recommended in Europe for non-small cell lung cancer
July 29, 2019Sales and Marketing Cancer, NSCLC, Roche, lung cancer, pharma, tecentriq
Riche’s blockbuster immunotherapy Tecentriq (atezolizumab) is closing in on securing yet another approval after it revealed that the drug was …
Sanofi ends partnership with Lexicon after release of Phase 3 data
July 29, 2019Sales and Marketing Lexicon, Sanofi, Zynquista, diabetes, pharma
French firm Sanofi has said it is ending its partnership with Texas-based firm Lexicon Pharmaceuticals over the development of diabetes …
FDA issues warning to CBD company Curaleaf
July 29, 2019Sales and Marketing CBD, FDA, cannabidiol, curaleaf, pharma, regulation
The FDA has issued a warning to Massachusetts-based CBD company Curaleaf over the firm’s use of unsubstantiated claims about the …
Novartis’ Entresto falls short at Phase 3 in heart failure with preserved ejection fraction
July 29, 2019Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma
Novartis has been rocked by new Phase 3 data from a global trial into the efficacy of Entresto (sacubitril/valsartan), revealing …
Bernie Sanders says price hiking pharma execs are murderers
July 29, 2019Sales and Marketing
Bernie Sanders has stood by his claim that those artificially raising the price for insulin are murderers. Speaking on Saturday …
Top Ten most popular articles on Pharmafile.com this week
July 26, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biohaven, FDA, Lyrica, NICE, Pfizer, UK, US, pharma, top ten
At the end of a week that could certainly be called “eventful” here in the UK – one that saw …
London’s water contains high levels of antibiotic-resistant genes, UCL research reveals
July 26, 2019Medical Communications, Research and Development London, UCL, UK, antibiotic resistance, pharma
Research from University College London has warned that freshwater sources in the English capital of London contain high levels of …
GW Pharma’s cannabis-based Epidyolex edges closer to EU approval with positive CHMP opinion in epilepsy
July 26, 2019Medical Communications, Sales and Marketing EMA, Epidiolex, Europe, GW Pharma, cannabis, epilepsy
UK-based biotech GW Pharmaceuticals has announced that its cannabidiol oral solution Epidyolex has secured recommendation from the European Medicines Agency’s …
J&J’s ponesimod meets primary and secondary endpoints at Phase 3 in relapsing multiple sclerosis
July 26, 2019Medical Communications, Research and Development Johnson & Johnson, multiple sclerosis, pharma, ponesimod
New Phase 3 data has been released on Johnson & Johnson’s selective sphingosine-1-phosphate receptor 1 (S1P1) modulator ponesimod, reporting that …
AstraZeneca’s Lynparza approved via Cancer Drugs Fund for BRCA+ gynaecological cancers
July 26, 2019Medical Communications, Sales and Marketing AstraZeneca, Cancer, Cancer Drugs Fund, NHS, NICE, UK, lynparza, pharma
NICE has published final guidance which approves AstraZeneca’s Lynparza (olaparib) for use on the NHS as a maintenance therapy for …
Vertex promote chief medical officer to CEO as Jeffrey Leiden steps down
July 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Dr Reshma Kewalramani has been made the new Vertex CEO. Vertex’s Chief Medical Officer Dr Kewalramani will succeed current CEO …
Christi Shaw taken on by Gilead as Kite Pharma’s new CEO
July 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Lilly veteran Christi Shaw has joined Kite Pharma as the company’s new CEO. Shaw comes to Gilead’s cancer immunotherapy firm, …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
